Cognitive impairment as a target for pharmacological treatment in schizophrenia.
Publication
, Journal Article
Davidson, M; Keefe, RS
Published in: Schizophr Res
September 1995
Duke Scholars
Published In
Schizophr Res
DOI
ISSN
0920-9964
Publication Date
September 1995
Volume
17
Issue
1
Start / End Page
123 / 129
Location
Netherlands
Related Subject Headings
- Schizophrenic Psychology
- Schizophrenia
- Psychiatry
- Nootropic Agents
- Neuropsychological Tests
- Humans
- Cognition Disorders
- Chronic Disease
- Antipsychotic Agents
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Davidson, M., & Keefe, R. S. (1995). Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res, 17(1), 123–129. https://doi.org/10.1016/0920-9964(95)00037-m
Davidson, M., and R. S. Keefe. “Cognitive impairment as a target for pharmacological treatment in schizophrenia.” Schizophr Res 17, no. 1 (September 1995): 123–29. https://doi.org/10.1016/0920-9964(95)00037-m.
Davidson M, Keefe RS. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res. 1995 Sep;17(1):123–9.
Davidson, M., and R. S. Keefe. “Cognitive impairment as a target for pharmacological treatment in schizophrenia.” Schizophr Res, vol. 17, no. 1, Sept. 1995, pp. 123–29. Pubmed, doi:10.1016/0920-9964(95)00037-m.
Davidson M, Keefe RS. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res. 1995 Sep;17(1):123–129.
Published In
Schizophr Res
DOI
ISSN
0920-9964
Publication Date
September 1995
Volume
17
Issue
1
Start / End Page
123 / 129
Location
Netherlands
Related Subject Headings
- Schizophrenic Psychology
- Schizophrenia
- Psychiatry
- Nootropic Agents
- Neuropsychological Tests
- Humans
- Cognition Disorders
- Chronic Disease
- Antipsychotic Agents
- 3202 Clinical sciences